JNJ-5207852 dihydrochloride

CAS No. 1782228-76-5

JNJ-5207852 dihydrochloride( —— )

Catalog No. M22976 CAS No. 1782228-76-5

JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi=8.9) and human (pKi=9.24) H3 receptor. JNJ-5207852 is a potent dibasic amine antagonist that binds potently to rat H3 receptors (Ki=1.2 nm), and has good brain penetration. In ex vivo binding studies in mice, the compound had an ED50 of 0.13 mg kg 1, subcutaneously.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 29 In Stock
5MG 41 In Stock
10MG 72 In Stock
25MG 145 In Stock
50MG 210 In Stock
100MG 304 In Stock
200MG 426 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JNJ-5207852 dihydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi=8.9) and human (pKi=9.24) H3 receptor. JNJ-5207852 is a potent dibasic amine antagonist that binds potently to rat H3 receptors (Ki=1.2 nm), and has good brain penetration. In ex vivo binding studies in mice, the compound had an ED50 of 0.13 mg kg 1, subcutaneously.
  • Description
    JNJ-5207852 is a novel, non-imidazole histamine H3 receptor antagonist, with high affinity at the rat (pKi=8.9) and human (pKi=9.24) H3 receptor. JNJ-5207852 is a potent dibasic amine antagonist that binds potently to rat H3 receptors (Ki=1.2 nm), and has good brain penetration. In ex vivo binding studies in mice, the compound had an ED50 of 0.13 mg kg 1, subcutaneously. It promotes wakefulness in rodents at 10 mg kg 1 s.c. but not at 1 mg kg 1, and significantly, this effect was absent in H3 receptor KO mice. JNJ-10181457 is also a dibasic amine antagonist that exhibits high-affinity binding for the rat H3 receptor (Ki=7.1 nm), promoting wakefulness in rodents and reducing cataplectic attacks in narcoleptic dogs . JNJ-10181457 improved cognitive performance in SHR pups at 10 mg kg 1.
  • In Vitro
    ——
  • In Vivo
    JNJ-5207852 (1-10mg/kg s.c.) increases time spent awake and decreases REM sleep and slow-wave sleep, but fails to have an effect on wakefulness or sleep in H3 receptor knockout mice. The wake promoting effects of this H3 receptor antagonist are not associated with hypermotility. A 4-week daily treatment of mice with JNJ-5207852 (10 mg/kg i.p.) does not lead to a change in body weight. JNJ-5207852 is extensively absorbed after oral administration and reaches high brain levels. Animal Model:Male, Sprague-Dawley ratsweighing 282-334 g.Dosage:3, 10, 30 mg/kg.Administration:S.C. Result:Iincreased time spent awake and decreased REM sleep and slow-wave sleep.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Histamine Receptor
  • Recptor
    H3 receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1782228-76-5
  • Formula Weight
    389.4
  • Molecular Formula
    C20H34Cl2N2O?
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [H]Cl.[H]Cl.N1(CCCOC2=CC=C(CN3CCCCC3)C=C2)CCCCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Esbenshade T A , Browman K E , Bitner R S , et al. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders[J]. 2008, 154(6):1166-1181.
molnova catalog
related products
  • Lodoxamide trometham...

    Lodoxamide tromethamine is a mast cell stabilizer with anti-allergic properties and can be used in studies about the treatment of asthma and allergic conjunctivitis.

  • Metiamide

    Metiamide is a histamine H2-receptor antagonist .

  • JNJ 39758979

    A potent, selective, orally bioavailable histamine H4 receptor antagonist with Ki of 12.5 nM.